I have been in New York and attending part of the Merrill Lynch healthcare investor conference. It has been a chance to see old friends, many of whom I had not seen in years. Posting has been non-existent this week but I expect to make up for this soon.
Expanding the theme of drug development ,watching the presentation of Genentech was a thing of beauty. Unfortunately the slides are not available on their webcast or I would include some examples. The breadth of the development could serve as a textbook, even for senior participants in the industry. The company is :able to seek optimum dose and regimens doing broad phase II studies, able to use government sponsored cooperative groups to enroll large numbers of patients and leverage their efforts and coordinate their efforts with corporate partners. Moreover they were able to convey the clarity of their efforts, always a positive both operationally and from an investor’s perspective.
When I return I will attempt a longer post on inhibitors of VEG-F(Vascular Endothelial Growth Factor) inhibition as anti cancer agents.
I got my first hit via a google search (bipolar Teddy Roosevelt).
Comments